好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sandman Send Me a Dream: Case of Non-24-Hour Sleep-Wake Disorder in a Sighted Pediatric Patient
Child Neurology and Developmental Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
4-005

Non-24-hour sleep-wake disorder (N24SWD) is a circadian rhythm disorder that leads to the inability to consistently sync the sleep wake (SW) pattern to the 24 hour day night cycle. Patients with N24SWD have progressively delayed SW patterns that occur in a cyclic fashion leading to significant interruptions to daily life. N24SWD is most commonly observed in non-sighted individuals impacting an estimated 50% of that population. It is exceedingly rare in patients with sight, with the first published case in 1971. Furthermore, this is even rarer, if ever, previously described in the pediatric population.

A 12-year-old male was referred for excessive daytime sleepiness and abnormal sleeping patterns. His bedtime is progressively more delayed each day. During periods of unrestricted sleep, sleep onset delays 2-3 hours each night, with a sleep latency of about 30 minutes and 8-10 hours of sleep duration. Return to a normal bedtime of 9:00pm occurs every 7-10 days. There was no other significant sleep history. He denies sleep paralysis, hypnogogic and hypnopompic hallucinations, and snoring. Melatonin had inconsistent success and adverse effects. The patient’s neurological examination was unremarkable.

NA

Actigraphy confirmed the diagnosis of N24SWD demonstrating cycling of SW when allowed a free sleep schedule. Brain MRI without contrast was unremarkable. The patient was initiated on tasimelteon which led to significant improvements in his ability to maintain a consistent bedtime. 

This case demonstrates that not only can N24SWD occur in sighted individuals, but it can certainly be present in the sighted pediatric population. If not identified, it can lead to long term effects on a child’s life, affecting their development and education. This case also demonstrated the benefits of selective melatonin agonists in the treatment of this condition.

Authors/Disclosures
Matthew Hart, MD
PRESENTER
Dr. Hart has nothing to disclose.
Alyssa M. Smith, MD (University of Rochester Medical Center) Dr. Smith has nothing to disclose.
Anne M. Morse, DO (Geisinger Medical Center) Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Morse has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Avadel. Dr. Morse has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Harmony Biosciences. Dr. Morse has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alkermes. Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Takeda. Dr. Morse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals. Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel. Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Avadel. Dr. Morse has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Harmony biosciences. Dr. Morse has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Hayes solicitors. Dr. Morse has received publishing royalties from a publication relating to health care. Dr. Morse has received personal compensation in the range of $100,000-$499,999 for serving as a CEO with DAMM Good Sleep, LLC.